Evolving Evidence and Treatment Strategies in Platinum Resistant Ovarian Cancer: From Biology to Bedside
Activity Overview
The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to join us for the Evolving Evidence and Treatment Strategies in Platinum Resistant Ovarian Cancer: From Biology to Bedside, an Educational Symposium being presented at the FSGO 2026 Annual Meeting in Long Boat Key, Florida a on Friday, June 12, 2026 from 11:45 am – 1:00 pm ET.
This educational activity is supported by an independent medical education grant from Corcept Therapeutics
Course Description
Platinum‑resistant ovarian cancer (PROC) remains a major therapeutic challenge due to modest survival outcomes and frequent treatment resistance. This CME session delivers a science‑forward, methodologic update designed to help clinicians interpret evolving evidence and educate the audience on thoughtful practice-based approach. Faculty will cover the current treatment landscape and survival benchmarks; mechanisms of resistance that inform next‑generation strategies; a masterclass in interpreting Phase 3 data (design, endpoints, and external validity); and equity and access considerations including biomarker testing logistics, clinical trial access, and shared decision‑making. Through a moderated panel, attendees will contextualize new evidence, anticipate how pending regulatory decisions may impact care, and identify research implications.
Target Audience
Gynecologic and medical oncologists, oncology researchers, clinical trial investigators, advanced practice providers, and healthcare professionals involved in the care of patients with ovarian cancer.
Learning Objectives
Upon completion of the activities in this series, learners will be able to:
- Summarize the current U.S. treatment landscape and unmet needs in platinum‑resistant ovarian cancer, including survival benchmarks and patterns of progression.
- Explain key biological drivers of resistance (e.g., DNA damage repair, replication stress, microenvironmental/immune factors) and how they inform therapeutic rationale and trial design.
- Critically interpret Phase 3 evidence (HRs, PFS/OS hierarchy, censoring, subgroup analyses, external validity) to guide evidence‑based practice.
- Apply biomarker information (e.g., FRα, BRCA, HRD) pragmatically—recognizing testing access, turnaround, and interpretation challenges—without referencing specific products.
- Engage in case‑based decision‑making and articulate how pending FDA decisions and guideline updates may shape future patient selection and sequencing.
Moderator
Thomas Herzog, MD
University of Cincinnati
Faculty
Rebecca Arend, MD, MSPH
O’Neal Comprehensive Cancer Center
R. Wendel Naumann, MD
Atrium Health Wak Forest Baptist Comprehensive Cancer Center
Agenda
Evolving Evidence and Treatment Strategies in Platinum Resistant Ovarian Cancer: From Biology to Bedside, an Educational Symposium at the 2026 FSGO Annual Meeting.
This session is not included in the main event CME/CPD credit.
Thomas Herzog, MD, Univesity of Cincinnati
R. Wendel Naumann, MD, Atrium Health Wake Forest Baptisit Comprehesive Cancer Canter
Rebecca Arend, MD, MSPH, O’Neal Comprehensive Cancer Center
All Faculty
All Faculty
All Faculty
Accreditation Statement
The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.
The GOG Foundation, Inc. designates this internet live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Declaration
In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.
Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.
All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.
NEW TERM *An “ineligible company” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.